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Background
The EBV protein Latent Membrane Protein-1 (LMP1) is
known to constitutively activate B cells. The LMP1 sig-
naling pathway mimics that of CD40, a molecule
involved in dendritic cell activation and maturation.
Therefore we decided to evaluate the use of LMP1 as a
vaccine adjuvant for both dendritic cell therapeutic vac-
cines and DNA-based vaccines for HIV.
Methods
To determine activity, LMP1 was analyzed using a luci-
ferase report assay for NF-kB and IFN-b. To establish if
LMP1 could activate human monocyte-derived dendritic
cells (DC), LMP1 transfected DC were analyzed for acti-
vation/maturation markers and cytokines. DC migration
was determined using a transwell-migration assay.
LMP1 was also evaluated in a DNA vaccination/flu chal-
lenge mouse model. To determine the benefits of incor-
porating LMP1 into a DC therapeutic vaccine, LMP1
was tested in a tumor DC therapy mouse model.
Results
LMP1 activated high levels of NF-kB and IFN-b when
evaluated using a luciferase reported assay. On primary
DC, LMP1 induced DC activation, maturation, and
proinflammatory cytokines. LMP1 induced 2-fold higher
migration rates compared to the mature-DC control. As
a DNA vaccine for flu, the addition of LMP1 provided
superior TNF-a and IFN-g responses. LMP1 vaccinated
animals cleared virus more quickly and in the high-dose
lethal flu challenge, LMP1 afforded more protection.
Finally, LMP1 enhanced a DC therapeutic vaccine in a
tumor model. Tumor progression was slowed compared
to antigen-loaded DC alone and positive control mimic-
matured DC.
Conclusion
These data suggest that LMP1 is an effective vaccine
adjuvant. LMP1 can enhance the activation, maturation,
and functional activity of DC. LMP1 can inducing a
strong CD8+ T cell response in several mouse models,
most notably the flu viral challenge model. LMP1
increased antigen-specific CD8+ T cells, improved survi-
val to lethal flu high-dose challenge, and slowed tumor
progression. These results suggest that LMP1 is a pro-
mising adjuvant for prophylactic vaccines for HIV.
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